文献速递头颈外科

临床淋巴结阴性涎腺恶性肿瘤患者的隐匿性淋巴结转移

Occult Nodal Metastases in Individuals with Clinically Node-Negative Salivary Gland Malignancies.
PubMed 文献 · Laryngoscope · 2023-10-17

该回顾性研究纳入532例临床淋巴结阴性涎腺恶性肿瘤患者,其中大涎腺癌389例、小涎腺癌143例。腮腺隐匿性淋巴结转移率为27%(63/235),颌下腺/舌下腺为35%(18/52),小涎腺为15%(4/26);颌下腺/舌下腺及小涎腺癌的隐匿性转移主要位于I-III区。作者据此认为可考虑在这些区域行选择性颈清扫。

要点

  • 腮腺癌隐匿性淋巴结转移率为27%(63/235),颌下腺/舌下腺癌为35%(18/52),小涎腺癌为15%(4/26)。
  • 颌下腺/舌下腺及小涎腺癌的隐匿性淋巴结转移主要分布于I-III区。
  • 作者认为上述部位肿瘤可考虑行I-III区选择性颈清扫。

核心结论

  • 颌下腺/舌下腺及小涎腺癌的隐匿性淋巴结转移主要位于I-III区,作者认为可考虑在这些区域行选择性颈清扫。

研究设计与样本

  • 回顾性病历回顾研究,共纳入532例临床淋巴结阴性涎腺恶性肿瘤患者,其中大涎腺癌389例、小涎腺癌143例。

主要发现

  • 腮腺癌隐匿性淋巴结转移率为27%(63/235),颌下腺/舌下腺癌为35%(18/52),小涎腺癌为15%(4/26)。
  • 各淋巴结区隐匿性转移分析显示,IV区和V区转移率高于既往研究。
  • 颌下腺/舌下腺及小涎腺癌的隐匿性转移主要位于I-III区。
  • 生存率及复发率与既往研究相似。

临床怎么用

  • 作者认为颌下腺/舌下腺及小涎腺癌可考虑行I-III区选择性颈清扫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Salivary gland malignancies comprise a heterogeneous group of pathologies, for which treatment of the clinically negative neck may vary depending on numerous factors. Herein we present data on occult nodal metastases (ONM) as well as survival and recurrence from a large series of cN0 salivary gland malignancies. METHODS: Retrospective chart review was conducted on 532 patients, with 389 patients with major salivary gland cancers and 143 patients with minor salivary gland cancers. Demographic and treatment data were included and rates of ONM, overall survival, local recurrence, regional recurrence, and distant recurrence were analyzed. RESULTS: We found that the overall rate of ONM for parotid was 27% (63/235), for submandibular/sublingual was 35% (18/52), and for minor was 15% (4/26). Analysis of ONM rate at each nodal level was also performed, finding higher rates of level IV and V ONM than prior studies. Submandibular/sublingual and minor salivary gland malignancies showed a predominance of ONMs at levels I-III. Our survival and recurrence rates were similar to those found in previous studies. CONCLUSION: Our data also demonstrate a predominance of ONM in levels I-III for submandibular/sublingual and minor salivary gland cancers, suggesting elective dissection in these levels. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:1705-1715, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Zhang ES, Hair BB, Lamarre ED, et al. Occult Nodal Metastases in Individuals with Clinically Node-Negative Salivary Gland Malignancies. Laryngoscope. 2023. PMID: 37847121. doi:10.1002/lary.31119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。